Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study

BACKGROUND: Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy escalation. OBJECTIVE: To investigate the safety and efficacy of off-label t...

Descripción completa

Detalles Bibliográficos
Autores principales: Torgauten, Hilde Marie, Myhr, Kjell-Morten, Wergeland, Stig, Bø, Lars, Aarseth, Jan H, Torkildsen, Øivind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970692/
https://www.ncbi.nlm.nih.gov/pubmed/33796328
http://dx.doi.org/10.1177/2055217320973049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970692/
https://www.ncbi.nlm.nih.gov/pubmed/33796328
http://dx.doi.org/10.1177/2055217320973049

Ejemplares similares